215 related articles for article (PubMed ID: 36379208)
1. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Sklavenitis-Pistofidis R; Aranha MP; Redd RA; Baginska J; Haradhvala NJ; Hallisey M; Dutta AK; Savell A; Varmeh S; Heilpern-Mallory D; Ujwary S; Zavidij O; Aguet F; Su NK; Lightbody ED; Bustoros M; Tahri S; Mouhieddine TH; Wu T; Flechon L; Anand S; Rosenblatt JM; Zonder J; Vredenburgh JJ; Boruchov A; Bhutani M; Usmani SZ; Matous J; Yee AJ; Jakubowiak A; Laubach J; Manier S; Nadeem O; Richardson P; Badros AZ; Mateos MV; Trippa L; Getz G; Ghobrial IM
Cancer Cell; 2022 Nov; 40(11):1358-1373.e8. PubMed ID: 36379208
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.
Nooka AK; Wang ML; Yee AJ; Kaufman JL; Bae J; Peterkin D; Richardson PG; Raje NS
JAMA Oncol; 2018 Dec; 4(12):e183267. PubMed ID: 30128502
[TBL] [Abstract][Full Text] [Related]
3. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
4. Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?
Maclachlan KH; Lesokhin AM
Cancer Cell; 2022 Nov; 40(11):1270-1272. PubMed ID: 36379204
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
Kazandjian D; Hill E; Dew A; Morrison C; Roswarski J; Korde N; Emanuel M; Petrosyan A; Bhutani M; Calvo KR; Dulau-Florea A; Kwok M; Lee MJ; Lee S; Lindenberg L; Mailankody S; Manasanch E; Maric I; Mena E; Patel N; Tageja N; Trepel JB; Turkbey B; Wang HW; Wang W; Yuan C; Zhang Y; Braylan R; Choyke P; Stetler-Stevenson M; Steinberg SM; Figg WD; Roschewski M; Landgren O
JAMA Oncol; 2021 Nov; 7(11):1678-1685. PubMed ID: 34529025
[TBL] [Abstract][Full Text] [Related]
6. Understanding high-risk smoldering multiple myeloma.
Kreiniz N; Gertz MA
Leuk Lymphoma; 2023; 64(8):1361-1372. PubMed ID: 37229535
[TBL] [Abstract][Full Text] [Related]
7. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Paiva B; Mateos MV; Sanchez-Abarca LI; Puig N; Vidriales MB; López-Corral L; Corchete LA; Hernandez MT; Bargay J; de Arriba F; de la Rubia J; Teruel AI; Giraldo P; Rosiñol L; Prosper F; Oriol A; Hernández J; Esteves G; Lahuerta JJ; Bladé J; Perez-Simon JA; San Miguel JF;
Blood; 2016 Mar; 127(9):1151-62. PubMed ID: 26668134
[TBL] [Abstract][Full Text] [Related]
8. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Musto P; Engelhardt M; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS
Haematologica; 2021 Nov; 106(11):2799-2812. PubMed ID: 34261295
[TBL] [Abstract][Full Text] [Related]
9. State of the science in smoldering myeloma: Should we be treating in the clinic?
Hill E; Dew A; Kazandjian D
Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
[TBL] [Abstract][Full Text] [Related]
10. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
Front Immunol; 2020; 11():613007. PubMed ID: 33488620
[TBL] [Abstract][Full Text] [Related]
11. The Role of Early Intervention in High-Risk Smoldering Myeloma.
Joseph NS; Dhodapkar MV; Lonial S
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-9. PubMed ID: 32182141
[TBL] [Abstract][Full Text] [Related]
12. Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials.
Ojo AS; Akinyemi O; Araoye MO; Ali A
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e27-e40. PubMed ID: 36402701
[TBL] [Abstract][Full Text] [Related]
13. Smoldering Multiple Myeloma: To Treat or Not to Treat.
Kapoor P; Rajkumar SV
Cancer J; 2019; 25(1):65-71. PubMed ID: 30694862
[TBL] [Abstract][Full Text] [Related]
14. Progress in the Management of Smoldering Multiple Myeloma.
Schmidt TM; Callander NS
Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
[TBL] [Abstract][Full Text] [Related]
15. Smoldering multiple myeloma current treatment algorithms.
Rajkumar SV; Kumar S; Lonial S; Mateos MV
Blood Cancer J; 2022 Sep; 12(9):129. PubMed ID: 36064707
[TBL] [Abstract][Full Text] [Related]
16. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Kunacheewa C; Manasanch EE
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
[TBL] [Abstract][Full Text] [Related]
17. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
18. Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients.
Vuckovic S; Bryant CE; Lau KHA; Yang S; Favaloro J; McGuire HM; Clark G; de St Groth BF; Marsh-Wakefield F; Nassif N; Abadir E; Vanguru V; McCulloch D; Brown C; Larsen S; Dunkley S; Khoo L; Gibson J; Boyle R; Joshua D; Ho PJ
Blood Adv; 2020 Oct; 4(19):4593-4604. PubMed ID: 32986791
[TBL] [Abstract][Full Text] [Related]
19. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.
Zavidij O; Haradhvala NJ; Mouhieddine TH; Sklavenitis-Pistofidis R; Cai S; Reidy M; Rahmat M; Flaifel A; Ferland B; Su NK; Agius MP; Park J; Manier S; Bustoros M; Huynh D; Capelletti M; Berrios B; Liu CJ; He MX; Braggio E; Fonseca R; Maruvka YE; Guerriero JL; Goldman M; Van Allen EM; McCarroll SA; Azzi J; Getz G; Ghobrial IM
Nat Cancer; 2020 May; 1(5):493-506. PubMed ID: 33409501
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.
Termini R; Žihala D; Terpos E; Perez-Montaña A; Jelínek T; Raab M; Weinhold N; Mai EK; Grab AL; Corre J; Vergez F; Sacco A; Chiarini M; Giustini V; Tucci A; Rodriguez S; Moreno C; Perez C; Maia C; Martín-Sánchez E; Guerrero C; Botta C; Garces JJ; Lopez A; Tamariz-Amador LE; Prosper F; Bargay J; Cabezudo ME; Ocio EM; Hájek R; Martinez-Lopez J; Solano F; Iglesias R; Paiva A; Geraldes C; Vitoria H; Gomez C; De Arriba F; Ludwig H; Garcia-Guiñon A; Casanova M; Alegre A; Cabañas V; Sirvent M; Oriol A; de la Rubia J; Hernández-Rivas JÁ; Palomera L; Sarasa M; Rios P; Puig N; Mateos MV; Flores-Montero J; Orfao A; Goldschmidt H; Avet-Loiseau H; Roccaro AM; San-Miguel JF; Paiva B;
Clin Cancer Res; 2022 Nov; 28(21):4771-4781. PubMed ID: 36074126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
